Heat shock proteins (Hsps) are highly expressed in a variety of cancer cells and are essential to their survival contributing to tumor cell propagation, metastasis, and protection against apoptosis]. Cancer is a leading cause of death worldwide. The current anti-cancer drugs available in market are not target specific and pose several side-effects and complications in clinical management of various forms of cancer, which highlights the urgent need for novel effective and less-toxic therapeutic approaches. Medicinal mushrooms have emerged as wonderful source of nutraceuticals, anti-oxidants, anticancer, prebiotic, anti-inflammatory, cardiovascular, anti-microbial, and anti-diabetic. The ongoing research projects are aimed to promote mushrooms as new generation ‘‘biotherapeutics". The aim of this study was to evaluate whether the cold-water extracts of Pleurotus eryngii var. eryngii can affect Hsp90, 70, 60 and 27 levels in an in vitro model of colon cancer (C26 cells). Cell viability was evaluated using MTT assay after treating the cells with different concentrations of extracts (0-1.9 μg/μl) in the culture medium for 24 and 48 hours. Hsp90, 70, 60 and 27 levels were measured using western blotting and immunofluorescence analysis. Moreover, we evaluated the anticancer effect of the P. eryngii var. eryngii extract in an animal model of ectopically-implanted C26 colon carcinoma, widely used as an experimental model of cancer cachexia. We prepared a mixture of lyophilized P. eryngii var. eryngii with the mice standard diet and the animals were daily fed with ~4g of the mix until they died to draw a survival curve. Our results showed that the extract significantly decreased cells viability at 0.48 μg/μl after both 24 and 48 hours of treatments. Western blotting analysis and immunofluorescence showed that Hsp60 protein levels were down-regulate at 24h of treatment but increased after 48h. On the contrary, Hsp90, 70 and 27 protein levels did not changed. In the in vivo model, P. eryngii var. eryngii in the diet significantly extended the median survival compared to untreated mice. These preliminary results are promising for further studies to better understand the potential anticancer effect of P. eryngii var. eryngii.
Marino Gammazza, A., Barone, R., Gargano, M.L., Caruso Bavisotto, C., Macaluso, F., D'Amico, D., et al. (2017). Anti-cancer effects of Pleurotus eryngii var. eryngii: an in vitro and in vivo models focusing on Heat Shock Proteins. In The 9th International Medicinal Mushrooms Conference-Book of Abstracts- Advances in Medicinal Mushroom Science: Building Bridges between Western and Eastern Medicine (pp.71-72). Palermo : Maria Letizia Gargano & Giuseppe Venturella.
Anti-cancer effects of Pleurotus eryngii var. eryngii: an in vitro and in vivo models focusing on Heat Shock Proteins
Marino Gammazza, AMembro del Collaboration Group
;Barone, RMembro del Collaboration Group
;Gargano, MLMembro del Collaboration Group
;Caruso Bavisotto, CMembro del Collaboration Group
;Macaluso, FMembro del Collaboration Group
;D'Amico, DMembro del Collaboration Group
;TROVATO, EleonoraMembro del Collaboration Group
;Rappa, FMembro del Collaboration Group
;Campanella, CMembro del Collaboration Group
;Di Felice, VMembro del Collaboration Group
;Cappello, FMembro del Collaboration Group
;Venturella, GMembro del Collaboration Group
2017-01-01
Abstract
Heat shock proteins (Hsps) are highly expressed in a variety of cancer cells and are essential to their survival contributing to tumor cell propagation, metastasis, and protection against apoptosis]. Cancer is a leading cause of death worldwide. The current anti-cancer drugs available in market are not target specific and pose several side-effects and complications in clinical management of various forms of cancer, which highlights the urgent need for novel effective and less-toxic therapeutic approaches. Medicinal mushrooms have emerged as wonderful source of nutraceuticals, anti-oxidants, anticancer, prebiotic, anti-inflammatory, cardiovascular, anti-microbial, and anti-diabetic. The ongoing research projects are aimed to promote mushrooms as new generation ‘‘biotherapeutics". The aim of this study was to evaluate whether the cold-water extracts of Pleurotus eryngii var. eryngii can affect Hsp90, 70, 60 and 27 levels in an in vitro model of colon cancer (C26 cells). Cell viability was evaluated using MTT assay after treating the cells with different concentrations of extracts (0-1.9 μg/μl) in the culture medium for 24 and 48 hours. Hsp90, 70, 60 and 27 levels were measured using western blotting and immunofluorescence analysis. Moreover, we evaluated the anticancer effect of the P. eryngii var. eryngii extract in an animal model of ectopically-implanted C26 colon carcinoma, widely used as an experimental model of cancer cachexia. We prepared a mixture of lyophilized P. eryngii var. eryngii with the mice standard diet and the animals were daily fed with ~4g of the mix until they died to draw a survival curve. Our results showed that the extract significantly decreased cells viability at 0.48 μg/μl after both 24 and 48 hours of treatments. Western blotting analysis and immunofluorescence showed that Hsp60 protein levels were down-regulate at 24h of treatment but increased after 48h. On the contrary, Hsp90, 70 and 27 protein levels did not changed. In the in vivo model, P. eryngii var. eryngii in the diet significantly extended the median survival compared to untreated mice. These preliminary results are promising for further studies to better understand the potential anticancer effect of P. eryngii var. eryngii.File | Dimensione | Formato | |
---|---|---|---|
BOOK of ABSTRACTS IMMC9-compresso.pdf
Solo gestori archvio
Descrizione: Book of Abstracts
Dimensione
3.56 MB
Formato
Adobe PDF
|
3.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.